Qure.ai and Project Data Sphere, a nonprofit initiative of the CEO Roundtable on Cancer, are partnering to improve tumor assessments using AI-enabled tools for clinical trials and cancer care.
The collaboration aims to increase efficiency and consistency in evaluating the effectiveness of cancer treatments through the use of autoRECIST, a product of Project Data Sphere’s Images and Algorithms program. The program, which began in consultation with the U.S. Food and Drug Administration (FDA), includes stakeholders and experts from across the pharmaceutical industry and academia.
Through the partnership, autoRECIST will address the need for automating and standardizing tumor response assessments in medical imaging to improve cancer treatment and research. The resulting AI tool will assist radiologists in the detection, selection, measuring, and tracking of lesions using defined criteria, according to Qure.ai.
